Volume : 13, Issue : 01, January – 2026
Title:
DEVELOPMENT AND CHARACTERIZATION OF VENLAFAXINE EXTENDED-RELEASE BILAYER TABLET
Authors :
Dr. Alladi Saritha*, Sravanthi
Abstract :
The present study aimed to develop and evaluate venlafaxine extended-release bilayer tablets capable of providing an initial loading dose followed by a sustained drug release for up to 12 hours. The bilayer system consisted of an immediate-release layer to achieve rapid onset of action and a sustained-release layer to maintain therapeutic plasma concentration. Tablets were prepared by direct compression using suitable polymers and excipients, and were subjected to standard pre- and post-compression evaluations including weight variation, thickness, hardness, friability and drug content. All formulations showed acceptable physical properties: hardness 5.2–5.6 kg/cm², friability <0.4 % and weight variation within pharmacopeial limits, confirming good mechanical strength and uniformity. In-vitro dissolution studies revealed an initial release of approximately 23–29 % of venlafaxine within the first hour, followed by a controlled and nearly linear release pattern. By 12 hours, cumulative drug release ranged from 93 % to 98 %, indicating successful extended-release characteristics. Among the eight formulations (F1–F8), F7 exhibited the most desirable profile with adequate burst release and highest cumulative release at 12 hours. The study demonstrates that a bilayer tablet approach is an effective oral drug delivery system for venlafaxine, providing both rapid onset and prolonged therapeutic action, and may improve patient compliance in the management of depressive disorders.
Keywords: Venlafaxine, Polymers, Extended release, Direct compression parameters, Bilayer tablets, In vitro drug release
Cite This Article:
Please cite this article in press Alladi Saritha et al., Development And Characterization Of Venlafaxine Extended-Release Bilayer Tablet, Indo Am. J. P. Sci, 2026; 13(01).
REFERENCES:
1. Deshpande RD, Gowda DV, Mahammed N, Maramwar DN. Bi-layer tablets-An emerging trend: a review. International journal of pharmaceutical sciences and research. 2011 Oct 1; 2(10):2534-2544.
2. Reddy KR, Mutalik S, Reddy S. Once-daily sustained-release matrix tablets of nicorandil: formulation and in vitro evaluation. AAPS pharm SciTech. 2003 Dec 1; 4(4):480-488.
3. Kanvinde SA, Kulkarni MS. Stability of oral solid dosage forms–A global perspective. Pharma times. 2005 May; 37(5):9-16.
4. Gohel MC, Bariya SH. Fabrication of triple-layer matrix tablets of Venlafaxine using xanthan gum. AAPS Pharmscitech. 2009 ;10(2):624-630.
5. Momin MM, Kane S, Abhang P. Formulation and evaluation of bilayer tablet for bimodal release of Venlafaxine . Front Pharmacol. 2015 Jul 9;6:144.
6. Reddy RK and SrinivasN. Formulation and evaluation of bilayered tablets of losartan potassium. IP. 2014;2(1):312-320. 14. Prakash VK and Shankar UB. Formulations and evaluation of ibuprofen floating tablets. IJPCBS. 2012;2(4):47-481.
7. Sandeep N and GuptaMM. Immediate drug release dosage form a review. JDDT. 2013;3(2):155-161.
8. Pateriya A, Bhowmick M, Pandey GK, Joshi A and Dubey BR. Formulation and evaluation of player tablets of candesartan and hydrochlorothiazide for the treatment of hypertension. JDDT. 2013;3(6):21-35.
9. Kumar HG, Jaganathan K, Kumar SR and Peruma lP. Formulation and invitroevaluation of bilayer floating tablets of metformin hydrochloride and sitagliptin phosphate. Intern J Pharma Resea. 2013;5(1):53-59.
10. Kumar HA, Kavitha K,Kumar SA,Kumar RM and Singh JSD. Novel approach of bilayer tablet technology are view. IJPCBS. 2013;3(3):887-893.
11. Sahota R, Singh G, Mankoo P, Kaur R, Singh S, Nagpal M, Upendra K and JainUK, Shelly KS and Sharma M. Development and characterization of bilayer tablets containing metformin hydrochloride sustained release layer and atorvastatin calcium in the immediate release layer. IPP. 2013;1(3):220-229.
12. Chaudhari S, Bawaskar M and Shirsat A. Formulation and evaluation of player floating tablet of carvedilol phosphate. JDDT. 2012;2(5):9-19. 21. Indian Pharmacopoeia. The Controller of Publication, Delhi. 1996; 2: 735.
13. Siepmann J, Peppas NA. HPMC matrices for controlled drug delivery: new model combining diffusion, swelling and dissolution mechanisms and predicting the release kinetics, Pharm Research, 2000; 16: 1748-1756.
14. Bhargav Bhongiri*, Vadivelan Ramachandran, and Raman Suresh Kumar. “Preformulation Studies of S-Equol.” Journal of Pharmaceutical Negative Results, 2022, 1020-1029.IF-0.654.